Jump to Main Content


FDA Grants Accelerated Approval to Blinatumomab for the Treatment of Adult and Pediatric Patients with B-cell Precursor Acute Lymphoblastic Leukemia

The Food and Drug Administration granted accelerated approval to blinatumomab (Blincyto, Amgen Inc.) for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.